On May 25, 2022 Chimeric Therapeutics Ltd (ASX:CHM) reported that it has exercised its exclusive option for the CORE-NK platform from Case Western Reserve University (CWRU) (Press release, Chimeric Therapeutics, MAY 25, 2022, View Source [SID1234614976]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The move will allow the clinical-stage cell therapy company to proceed with negotiations for an exclusive licence.

Chimeric has had six months to exercise this option, provided it met certain milestones in accordance with an agreed development plan.

The Clinically validated, Off the shelf, Robust, Enhanced Natural Killer (CORE-NK) cell platform technology provides an excellent foundation for accelerated development of multiple next generation NK and CAR-NK products.

In March 2022, Chimeric delivered positive final results from a Phase 1 trial of the platform conducted in blood cancers and solid tumours.

Read: Chimeric Therapeutics concludes safety trial for blood and solid tumour cancer treatment; one patient in remission

Chimeric expects to use the CORE-NK platform while leveraging its existing portfolio of CARs to pursue new clinical trials in blood cancers and solid tumours beginning in 2023.